- Home
- KLRS vs RDI Comparison
KLRS vs RDI Comparison
Compare KLRS & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | RDI |
|---|---|---|
| Founded | 2019 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 49.0M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KLRS | RDI |
|---|---|---|
| Price | $1.55 | $1.98 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | ★ 70.4K | 22.2K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.70 | 60.76 |
| EPS | N/A | ★ N/A |
| Revenue | $165,000.00 | ★ $202,988,000.00 |
| Revenue This Year | N/A | $15.10 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $0.94 |
| 52 Week High | $11.88 | $2.41 |
Technical Indicators
Market Signals| Indicator | KLRS | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 65.07 |
| Support Level | N/A | $1.64 |
| Resistance Level | $2.66 | $2.13 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 0.00 | 96.34 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.